Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) EBIT: 2023-2024

Historic EBIT for Artiva Biotherapeutics (ARTV) over the last 2 years, with Dec 2024 value amounting to -$18.3 million.

  • Artiva Biotherapeutics' EBIT fell 52.61% to -$18.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$67.3 million, marking a year-over-year change of. This contributed to the annual value of -$67.3 million for FY2024, which is 119.37% down from last year.
  • Per Artiva Biotherapeutics' latest filing, its EBIT stood at -$18.3 million for Q4 2024, which was up 0.37% from -$18.3 million recorded in Q3 2024.
  • Artiva Biotherapeutics' 5-year EBIT high stood at $10.8 million for Q3 2023, and its period low was -$18.3 million during Q3 2024.
  • For the 2-year period, Artiva Biotherapeutics' EBIT averaged around -$12.3 million, with its median value being -$16.2 million (2024).
  • Examining YoY changes over the last 5 years, Artiva Biotherapeutics' EBIT showed a top increase of 8.46% in 2024 and a maximum decrease of 269.60% in 2024.
  • Artiva Biotherapeutics' EBIT (Quarterly) stood at -$12.0 million in 2023, then slumped by 52.61% to -$18.3 million in 2024.
  • Its EBIT stands at -$18.3 million for Q4 2024, versus -$18.3 million for Q3 2024 and -$16.2 million for Q2 2024.